CD8A

Across TCGA pan-cancer cohorts, CD8A mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD8A data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CD8A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CD8A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where CD8A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.898	0.594	.002	29	view →
PDAC	DFS	Quartile	III,IV	0.979	0.439	.004	14	view →
LUAD	DFS	Tertile	All	0.956	0.894	.015	9	view →
HNSC	DFS	Median	II,III,IV	0.902	0.988	.006	9	view →
OV	DFS	Median	All	1.000	0.861	.035	4	view →
UCEC	DFS	Tertile	II,III,IV	0.409	0.891	.038	4	view →
LSCC	OS	Tertile	II,III,IV	0.498	0.885	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD8A–CCRCC (OS)

Open the CCRCC breakdown →